General discussion, page-5693

Although the Mindmed share price has been going all over the place, some interesting points regarding a US listing and diversification -

https://www.benzinga.com/markets/cannabis/21/04/20871913/exclusive-mindmeds-nasdaq-listing-enables-institutions-diversified-access-to-a-new-age-of-medici

A couple of snippets for those not wanting to clicky clicky linky linky:

In a move to bolster innovation and allow investors a chance to participate in the new age of medicine, MindMed listed on the Nasdaq, a brand that’s supported firms like Apple Inc (NASDAQ:AAPL), Alphabet Inc (NASDAQ:GOOGL), and Microsoft Corporation (NASDAQ:MSFT), at their earliest stages. “It was definitely a long process to get here,” Rahn noted. “Because of the high listing standard, Nasdaq is a great place to interact with institutional investors and ultimately enable us to allocate capital to these unmet medical needs in mental health.”

Aside from validation, diversification is a key barrier to investing for smart-money investors and institutions. Institutional investors, especially in junior pharma, are looking to mitigate risk and weight according to diversity across a few key metrics, according to O’Leary.

"...could achieve a superior market cap because of its diversification"